vs

Side-by-side financial comparison of Core Laboratories Inc. (CLB) and Inogen Inc (INGN). Click either name above to swap in a different company.

Core Laboratories Inc. is the larger business by last-quarter revenue ($121.8M vs $68.6M, roughly 1.8× Inogen Inc). On growth, Inogen Inc posted the faster year-over-year revenue change (3.4% vs -1.4%). Core Laboratories Inc. produced more free cash flow last quarter ($517.0K vs $-1.9M). Over the past eight quarters, Inogen Inc's revenue compounded faster (4.2% CAGR vs -3.4%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Inogen Inc is a medical technology firm specializing in the development, production and distribution of portable oxygen concentrators and associated respiratory care products. It caters primarily to patients with chronic respiratory conditions needing long-term oxygen therapy across North America, Europe and other global markets, focusing on home care and ambulatory patient segments to enhance users' quality of life.

CLB vs INGN — Head-to-Head

Bigger by revenue
CLB
CLB
1.8× larger
CLB
$121.8M
$68.6M
INGN
Growing faster (revenue YoY)
INGN
INGN
+4.9% gap
INGN
3.4%
-1.4%
CLB
More free cash flow
CLB
CLB
$2.4M more FCF
CLB
$517.0K
$-1.9M
INGN
Faster 2-yr revenue CAGR
INGN
INGN
Annualised
INGN
4.2%
-3.4%
CLB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLB
CLB
INGN
INGN
Revenue
$121.8M
$68.6M
Net Profit
$5.1M
Gross Margin
51.4%
Operating Margin
1.5%
-13.6%
Net Margin
4.2%
Revenue YoY
-1.4%
3.4%
Net Profit YoY
EPS (diluted)
$0.11
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLB
CLB
INGN
INGN
Q1 26
$121.8M
Q4 25
$138.3M
$68.6M
Q3 25
$134.5M
$79.1M
Q2 25
$130.2M
$79.2M
Q1 25
$123.6M
$68.5M
Q4 24
$129.2M
$66.3M
Q3 24
$134.4M
$74.9M
Q2 24
$130.6M
$74.4M
Net Profit
CLB
CLB
INGN
INGN
Q1 26
$5.1M
Q4 25
$4.9M
Q3 25
$14.2M
$-5.3M
Q2 25
$10.6M
$-4.2M
Q1 25
$-154.0K
$-6.2M
Q4 24
$7.4M
Q3 24
$11.7M
$-6.0M
Q2 24
$9.0M
$-5.6M
Gross Margin
CLB
CLB
INGN
INGN
Q1 26
Q4 25
20.8%
51.4%
Q3 25
22.0%
52.2%
Q2 25
20.3%
52.2%
Q1 25
19.5%
53.1%
Q4 24
17.8%
54.7%
Q3 24
20.5%
55.2%
Q2 24
21.2%
57.4%
Operating Margin
CLB
CLB
INGN
INGN
Q1 26
1.5%
Q4 25
11.5%
-13.6%
Q3 25
15.6%
-9.0%
Q2 25
11.7%
-7.7%
Q1 25
3.6%
-11.2%
Q4 24
11.0%
-17.2%
Q3 24
14.7%
-10.4%
Q2 24
12.3%
-9.5%
Net Margin
CLB
CLB
INGN
INGN
Q1 26
4.2%
Q4 25
3.6%
Q3 25
10.6%
-6.7%
Q2 25
8.2%
-5.2%
Q1 25
-0.1%
-9.0%
Q4 24
5.7%
Q3 24
8.7%
-8.0%
Q2 24
6.9%
-7.5%
EPS (diluted)
CLB
CLB
INGN
INGN
Q1 26
$0.11
Q4 25
$0.11
$-0.26
Q3 25
$0.30
$-0.20
Q2 25
$0.22
$-0.15
Q1 25
$0.00
$-0.25
Q4 24
$0.15
$-0.41
Q3 24
$0.25
$-0.25
Q2 24
$0.19
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLB
CLB
INGN
INGN
Cash + ST InvestmentsLiquidity on hand
$22.8M
$103.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$275.1M
$192.2M
Total Assets
$587.7M
$298.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLB
CLB
INGN
INGN
Q1 26
$22.8M
Q4 25
$22.7M
$103.7M
Q3 25
$25.6M
$106.5M
Q2 25
$31.2M
$103.7M
Q1 25
$22.1M
$118.9M
Q4 24
$19.2M
$113.8M
Q3 24
$21.5M
$105.7M
Q2 24
$17.7M
$97.9M
Total Debt
CLB
CLB
INGN
INGN
Q1 26
Q4 25
$110.3M
Q3 25
$114.1M
Q2 25
$124.6M
Q1 25
$124.4M
Q4 24
$126.1M
Q3 24
$139.9M
Q2 24
$147.6M
Stockholders' Equity
CLB
CLB
INGN
INGN
Q1 26
$275.1M
Q4 25
$266.0M
$192.2M
Q3 25
$271.3M
$197.2M
Q2 25
$261.3M
$199.5M
Q1 25
$253.4M
$198.0M
Q4 24
$246.6M
$173.9M
Q3 24
$250.7M
$185.4M
Q2 24
$240.3M
$187.6M
Total Assets
CLB
CLB
INGN
INGN
Q1 26
$587.7M
Q4 25
$584.0M
$298.6M
Q3 25
$591.4M
$307.0M
Q2 25
$602.1M
$312.0M
Q1 25
$591.5M
$308.4M
Q4 24
$585.1M
$296.2M
Q3 24
$600.5M
$306.2M
Q2 24
$597.8M
$308.9M
Debt / Equity
CLB
CLB
INGN
INGN
Q1 26
Q4 25
0.41×
Q3 25
0.42×
Q2 25
0.48×
Q1 25
0.49×
Q4 24
0.51×
Q3 24
0.56×
Q2 24
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLB
CLB
INGN
INGN
Operating Cash FlowLast quarter
$4.0M
$-943.0K
Free Cash FlowOCF − Capex
$517.0K
$-1.9M
FCF MarginFCF / Revenue
0.4%
-2.8%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
0.77×
TTM Free Cash FlowTrailing 4 quarters
$22.5M
$-13.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLB
CLB
INGN
INGN
Q1 26
$4.0M
Q4 25
$7.9M
$-943.0K
Q3 25
$8.5M
$2.2M
Q2 25
$13.9M
$4.3M
Q1 25
$6.7M
$-16.8M
Q4 24
$20.6M
$-3.0M
Q3 24
$13.1M
$7.0M
Q2 24
$17.1M
$6.7M
Free Cash Flow
CLB
CLB
INGN
INGN
Q1 26
$517.0K
Q4 25
$5.0M
$-1.9M
Q3 25
$6.5M
$1.6M
Q2 25
$10.4M
$3.7M
Q1 25
$3.9M
$-17.1M
Q4 24
$17.4M
$-3.3M
Q3 24
$10.4M
$5.3M
Q2 24
$14.3M
$6.6M
FCF Margin
CLB
CLB
INGN
INGN
Q1 26
0.4%
Q4 25
3.6%
-2.8%
Q3 25
4.8%
2.0%
Q2 25
8.0%
4.6%
Q1 25
3.1%
-24.9%
Q4 24
13.4%
-5.0%
Q3 24
7.7%
7.1%
Q2 24
10.9%
8.9%
Capex Intensity
CLB
CLB
INGN
INGN
Q1 26
Q4 25
2.1%
1.4%
Q3 25
1.5%
0.7%
Q2 25
2.7%
0.9%
Q1 25
2.3%
0.4%
Q4 24
2.5%
0.5%
Q3 24
2.0%
2.2%
Q2 24
2.2%
0.1%
Cash Conversion
CLB
CLB
INGN
INGN
Q1 26
0.77×
Q4 25
1.61×
Q3 25
0.60×
Q2 25
1.31×
Q1 25
Q4 24
2.78×
Q3 24
1.12×
Q2 24
1.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLB
CLB

Segment breakdown not available.

INGN
INGN

Other$36.1M53%
Non Us$32.5M47%

Related Comparisons